305 related articles for article (PubMed ID: 20167081)
1. Anti-tetherin activities in Vpu-expressing primate lentiviruses.
Yang SJ; Lopez LA; Hauser H; Exline CM; Haworth KG; Cannon PM
Retrovirology; 2010 Feb; 7():13. PubMed ID: 20167081
[TBL] [Abstract][Full Text] [Related]
2. Ancient adaptive evolution of tetherin shaped the functions of Vpu and Nef in human immunodeficiency virus and primate lentiviruses.
Lim ES; Malik HS; Emerman M
J Virol; 2010 Jul; 84(14):7124-34. PubMed ID: 20444900
[TBL] [Abstract][Full Text] [Related]
3. Species-specific activity of SIV Nef and HIV-1 Vpu in overcoming restriction by tetherin/BST2.
Jia B; Serra-Moreno R; Neidermyer W; Rahmberg A; Mackey J; Fofana IB; Johnson WE; Westmoreland S; Evans DT
PLoS Pathog; 2009 May; 5(5):e1000429. PubMed ID: 19436700
[TBL] [Abstract][Full Text] [Related]
4. Vpu of a Simian Immunodeficiency Virus Isolated from Greater Spot-Nosed Monkey Antagonizes Human BST-2 via Two AxxxxxxxW Motifs.
Yao W; Yoshida T; Hashimoto S; Takeuchi H; Strebel K; Yamaoka S
J Virol; 2020 Jan; 94(2):. PubMed ID: 31666374
[TBL] [Abstract][Full Text] [Related]
5. Differential sensitivities of tetherin isoforms to counteraction by primate lentiviruses.
Weinelt J; Neil SJ
J Virol; 2014 May; 88(10):5845-58. PubMed ID: 24623426
[TBL] [Abstract][Full Text] [Related]
6. Tetherin antagonism by primate lentiviral nef proteins.
Sauter D; Kirchhoff F
Curr HIV Res; 2011 Oct; 9(7):514-23. PubMed ID: 22103835
[TBL] [Abstract][Full Text] [Related]
7. Counteraction of tetherin antiviral activity by two closely related SIVs differing by the presence of a Vpu gene.
Nikovics K; Dazza MC; Ekwalanga M; Mammano F; Clavel F; Saragosti S
PLoS One; 2012; 7(4):e35411. PubMed ID: 22530020
[TBL] [Abstract][Full Text] [Related]
8. HIV-1 Group P is unable to antagonize human tetherin by Vpu, Env or Nef.
Sauter D; Hué S; Petit SJ; Plantier JC; Towers GJ; Kirchhoff F; Gupta RK
Retrovirology; 2011 Dec; 8():103. PubMed ID: 22171785
[TBL] [Abstract][Full Text] [Related]
9. Tetherin-driven adaptation of Vpu and Nef function and the evolution of pandemic and nonpandemic HIV-1 strains.
Sauter D; Schindler M; Specht A; Landford WN; Münch J; Kim KA; Votteler J; Schubert U; Bibollet-Ruche F; Keele BF; Takehisa J; Ogando Y; Ochsenbauer C; Kappes JC; Ayouba A; Peeters M; Learn GH; Shaw G; Sharp PM; Bieniasz P; Hahn BH; Hatziioannou T; Kirchhoff F
Cell Host Microbe; 2009 Nov; 6(5):409-21. PubMed ID: 19917496
[TBL] [Abstract][Full Text] [Related]
10. Efficient Vpu-Mediated Tetherin Antagonism by an HIV-1 Group O Strain.
Mack K; Starz K; Sauter D; Langer S; Bibollet-Ruche F; Learn GH; Stürzel CM; Leoz M; Plantier JC; Geyer M; Hahn BH; Kirchhoff F
J Virol; 2017 Mar; 91(6):. PubMed ID: 28077643
[TBL] [Abstract][Full Text] [Related]
11. Species-specific activity of HIV-1 Vpu and positive selection of tetherin transmembrane domain variants.
McNatt MW; Zang T; Hatziioannou T; Bartlett M; Fofana IB; Johnson WE; Neil SJ; Bieniasz PD
PLoS Pathog; 2009 Feb; 5(2):e1000300. PubMed ID: 19214216
[TBL] [Abstract][Full Text] [Related]
12. Vpu serine 52 dependent counteraction of tetherin is required for HIV-1 replication in macrophages, but not in ex vivo human lymphoid tissue.
Schindler M; Rajan D; Banning C; Wimmer P; Koppensteiner H; Iwanski A; Specht A; Sauter D; Dobner T; Kirchhoff F
Retrovirology; 2010 Jan; 7():1. PubMed ID: 20078884
[TBL] [Abstract][Full Text] [Related]
13. Lack of adaptation to human tetherin in HIV-1 group O and P.
Yang SJ; Lopez LA; Exline CM; Haworth KG; Cannon PM
Retrovirology; 2011 Sep; 8():78. PubMed ID: 21955466
[TBL] [Abstract][Full Text] [Related]
14. The transmembrane domain of HIV-1 Vpu is sufficient to confer anti-tetherin activity to SIVcpz and SIVgor Vpu proteins: cytoplasmic determinants of Vpu function.
Kluge SF; Sauter D; Vogl M; Peeters M; Li Y; Bibollet-Ruche F; Hahn BH; Kirchhoff F
Retrovirology; 2013 Mar; 10():32. PubMed ID: 23514615
[TBL] [Abstract][Full Text] [Related]
15. Simian immunodeficiency virus envelope glycoprotein counteracts tetherin/BST-2/CD317 by intracellular sequestration.
Gupta RK; Mlcochova P; Pelchen-Matthews A; Petit SJ; Mattiuzzo G; Pillay D; Takeuchi Y; Marsh M; Towers GJ
Proc Natl Acad Sci U S A; 2009 Dec; 106(49):20889-94. PubMed ID: 19864625
[TBL] [Abstract][Full Text] [Related]
16. HIV-1 Vpu and HIV-2 Env counteract BST-2/tetherin by sequestration in a perinuclear compartment.
Hauser H; Lopez LA; Yang SJ; Oldenburg JE; Exline CM; Guatelli JC; Cannon PM
Retrovirology; 2010 Jun; 7():51. PubMed ID: 20529266
[TBL] [Abstract][Full Text] [Related]
17. Adaptation of human and simian immunodeficiency viruses for resistance to tetherin/BST-2.
Serra-Moreno R; Evans DT
Curr HIV Res; 2012 Jun; 10(4):277-82. PubMed ID: 22524175
[TBL] [Abstract][Full Text] [Related]
18. Vpu directs the degradation of the human immunodeficiency virus restriction factor BST-2/Tetherin via a {beta}TrCP-dependent mechanism.
Douglas JL; Viswanathan K; McCarroll MN; Gustin JK; Früh K; Moses AV
J Virol; 2009 Aug; 83(16):7931-47. PubMed ID: 19515779
[TBL] [Abstract][Full Text] [Related]
19. A cytoplasmic tail determinant in HIV-1 Vpu mediates targeting of tetherin for endosomal degradation and counteracts interferon-induced restriction.
Kueck T; Neil SJ
PLoS Pathog; 2012; 8(3):e1002609. PubMed ID: 22479182
[TBL] [Abstract][Full Text] [Related]
20. Simian immunodeficiency virus SIVagm from African green monkeys does not antagonize endogenous levels of African green monkey tetherin/BST-2.
Lim ES; Emerman M
J Virol; 2009 Nov; 83(22):11673-81. PubMed ID: 19726508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
